Skip to content

#礼来

Today 0 items
Oct 9Fri
  1. biospace.com54

    TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms

    TRexBio raised $116.7 million in its Nasdaq IPO, selling 8.3 million shares at $14 to fund TRB-061, a fusion protein in early-stage development for atopic dermatitis with a Phase 1b topline readout expected mid-2027. Retension Pharmaceuticals raised $45 million at $12 per share to advance RTN-001, a PDE-5 blocker for hypertension, through Phase 2b and into Phase 3. City Therapeutics expects about $158.3 million and Iambic Therapeutics about $135 million from upcoming offerings.

    Why it matters: Four biotech IPOs in one week signal a reopening of the public markets for drug developers.

  2. biopharmadive.com61

    TRex Bio prices $117M IPO to support immune drug work

    TRex Bio priced a $117 million IPO, selling 8,333,334 shares at $14 each, and begins trading Friday on Nasdaq under "TRXB." The company is developing Treg-activating drugs for immunological conditions, including TRB-061, in a Phase 1 trial with topline data expected in 2027, and TRB-071 for inflammatory bowel disease, which could enter testing next year. Eli Lilly, TRex's largest equity holder at about 24% pre-IPO, and Johnson & Johnson have licensed or optioned treatments discovered by TRex, which has raised $220 million in venture financing to date.

    Why it matters: IPO shows continued investor appetite for immune-focused biotechs, with six of 23 drug developers going public in 2026 working on immune diseases.

Oct 7Wed
  1. biospace.com69

    Biotech VC Forbion raises record $2.6B to support 30 ‘high-potential’ companies

    Forbion has raised €2.3 billion ($2.6 billion) across two new funds, Growth Opportunities Fund IV and Ventures Fund VIII, its largest raise ever, to back some 30 high-potential drugmakers, from pre-clinical and early clinical-stage biotechs to private growth, crossover and public investments. Eli Lilly participated alongside KfW Capital, PGM and Kauffman Foundation. The Dutch firm now has approximately €7.5 billion ($8.42 billion) in assets under management across a portfolio of more than 140 companies.

    Why it matters: One of the largest life sciences VC raises in five years signals where biotech capital is flowing.

  2. biospace.com40

    Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

    Genmab and AbbVie's bispecific antibody Epkinly, approved in May 2023 for diffuse large B cell lymphoma after at least two prior systemic lines, cut risk of disease progression or death by 51% in a Phase 3 trial when combined with R-CHOP in the frontline setting. In deals, Shionogi bought IntraBio for $2 billion, Novartis committed up to $7.8 billion to Abogen Biosciences, Eli Lilly added up to $870 million with Gate Bioscience, and Sanofi and Regeneron renewed their collaboration with a $1 billion upfront. Sarepta shared Elevidys data in older Duchenne patients at the World Muscle Society meeting, with Jefferies citing upcoming readouts and an FDA decision on Amondys 45 and Vyondys 53.

  3. biopharmadive.com60

    Forbion, a prominent biotech investor, raises $2.6B for a pair of venture funds

    Forbion, a Netherlands-based venture firm focused on life sciences, raised 2.3 billion euros ($2.6 billion) across two funds, Forbion Growth Opportunities IV and Forbion Ventures Fund VIII, its largest fundraise to date. The funds have capacity to invest in as many as 30 young companies; recent investments include Sling Therapeutics and Solstice Oncology. Backers include MN, PGGM, the Kauffman Foundation, KfW Capital and Eli Lilly, and Forbion now has 7.5 billion euros under management.

    Why it matters: Europe's largest life sciences venture fund raised its biggest sum yet while European biotech faces declining investment and clinical trial activity.

Oct 6Tue
  1. biospace.com46

    Compliance concerns hinder rollout of AI in drug manufacturing: Survey

    Fewer than 10% of drugmakers are scaling AI in clinical or commercial manufacturing, according to a CRB survey of more than 400 R&D and manufacturing professionals for its 2026 Horizons report. Use is concentrated in nonregulated areas such as administrative workflows (56%) and drug discovery (45%), with accuracy and quality concerns and insufficient validation standards cited as the main barriers. CRB found that 31% of respondents plan to use AI in regulated manufacturing within three years, and another 31% are considering it without a formal plan.

    Why it matters: Shows regulatory and validation concerns are blocking AI adoption in drug manufacturing, with an FDA warning letter already issued.

Oct 5Mon
  1. biospace.com60

    Lilly doubles down on Gate alliance to unlock new drug class with another $870M+ in biobucks

    Eli Lilly has expanded its alliance with Gate Bioscience in a deal worth up to more than $870 million, adding one new target with the option of a second to their existing collaboration on Gate's Molecular Gate discovery engine for difficult-to-drug extracellular proteins. Gate, which signed an initial deal with Lilly worth up to $856 million in July 2025, will receive an undisclosed upfront payment plus payments on preclinical, clinical and commercial milestones and tiered royalties. Gate leads discovery while Lilly takes an exclusive worldwide license and handles development from later-stage preclinical work through commercialization; no indications have been disclosed.

    Why it matters: Lilly is committing another $870 million to Gate's Molecular Gate platform, deepening a fast-repeat collaboration on a new drug class.

  2. biopharmadive.com40

    Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug

    The Nobel Prize in Physiology or Medicine went to Peter Hegemann, Georg Nagel and Karl Deisseroth for optogenetics, a light-based method for studying neurons. Alector licensed its preclinical Parkinson's therapy AL050 to Roche's Genentech for $100 million in guaranteed cash and up to $1.17 billion in milestones plus royalties. Separately, the FDA approved Lilly's Jaypirca as a first-line treatment for CLL or SLL patients without a 17p deletion.

    Why it matters: Nobel recognition for optogenetics and a sizeable Roche-Alector brain drug deal matter to neuroscience-focused readers.

Oct 1Thu
  2. biospace.com54

    Foghorn lays off 40% of staff after Lilly collaboration ends

    Foghorn Therapeutics and Eli Lilly ended their oncology collaboration after Phase 1 data on cancer candidate FHD-909 (LY4050784) showed insufficient efficacy, halting its move into clinical development expansion and a SMARCA2 degrader program. Foghorn is cutting about 40% of its workforce, leaving roughly 65 full-time employees, and will refocus on its proprietary programs including EP300 and CBP degraders. The 2021 deal had brought $300 million upfront plus an $80 million equity investment from Lilly's Loxo Oncology, and the changes should extend Foghorn's cash runway into the second half of 2029.

    Why it matters: A terminated big-pharma oncology alliance triggers pipeline reprioritization, layoffs and a readout on the SMARCA2 synthetic lethality hypothesis.

Sep 24Thu
  1. fiercebiotech.com42

    Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare

    Eli Lilly will pay InnoCare Pharma $100 million in upfront and near-term payments for a five-target drug discovery collaboration, with up to $3.25 billion in potential milestones plus single-digit tiered royalties on net sales. Beijing-based InnoCare will apply its drug discovery platform to targets the partners have not disclosed, beyond saying the programs address critical unmet medical needs. The deal extends a Lilly deal spree funded by GLP-1 cash.

    Why it matters: Large China-US discovery pact shows Lilly continuing its GLP-1-funded deal spree.

Sep 9Wed
  1. statnews.com47

    STAT+: Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that idea

    Kura Oncology is spinning off its menin inhibitor programme into a new company, Caspian Therapeutics, which launches with $50 million in financing led by BVF Partners and joined by Eli Lilly. Animal studies of Kura's menin-targeting leukemia therapy showed the approach also helped control blood sugar, so Caspian will develop menin inhibitors for diabetes and other cardiometabolic diseases, taking its lead small molecule into an early-phase diabetes trial and backing a second candidate. Kura retains about 50% ownership, Kura CEO Troy Wilson becomes executive chair, and Robert Spencer was named to lead Caspian.

    Why it matters: A leukemia-derived menin inhibitor programme enters diabetes via a $50 million spinout with Eli Lilly involvement.

Sep 1Tue
  1. biocentury.com55

    Lilly’s deal spree continues with Merida takeout: Deals Report

    Eli Lilly has agreed to acquire Merida Biosciences, a four-year-old Cambridge, Massachusetts autoimmunity and allergy biotech, in a deal valued at up to $2.88 billion. The acquisition gives Lilly MER511, a Phase I Fc therapeutic that binds anti-TSHR autoantibodies for Graves' disease and thyroid eye disease. Merida raised a $121 million series A in 2025 co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures.

    Why it matters: Lilly's thirteenth takeout expands its autoimmune pipeline into Graves' disease and thyroid eye disease.

Aug 31Mon
Aug 18Tue
  1. biocentury.com40

    Slate, Redx to reach NASDAQ via reverse mergers: Deals Report

    Slate and Redx plan to reach NASDAQ through reverse mergers with shell companies, a route private biotechs continue to use as available shells pair with venture-backed start-ups. Syndicates have in many cases provided nine-digit sums in concurrent placements, letting companies list and raise cash without a traditional IPO. Separately, bankrupt Sangamo's assets go to Lilly and PTC.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org